Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant/Palonosetron for CINV in HNSCC
NCT06102447Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of netupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV) and radiotherapy-induced nausea and vomiting (RINV), sponsored by Sichuan Cancer Hospital. Primary endpoint: Complete response rate during synchronous radiotherapy and chemotherapy at 1 month. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
netupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)radiotherapy-induced nausea and vomiting (RINV)
Beyond the preview
Go deeper on NCT06102447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102447.